{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:48:40Z","timestamp":1791748120666,"version":"4.3.4"},"reference-count":138,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["RA230062"],"award-info":[{"award-number":["RA230062"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["KC240237P1"],"award-info":[{"award-number":["KC240237P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of War","doi-asserted-by":"publisher","award":["KCRP W81XWH-21-1-0942"],"award-info":[{"award-number":["KCRP W81XWH-21-1-0942"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002163","name":"Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA285454"],"award-info":[{"award-number":["R01CA285454"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA016672"],"award-info":[{"award-number":["P30-CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA288448"],"award-info":[{"award-number":["R37CA288448"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA196516"],"award-info":[{"award-number":["P50CA196516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.07.035","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:29:17Z","timestamp":1789270157000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Jason","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie I.","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Cost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arighno","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"Dizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Drago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minas","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasha","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth P.","family":"Henske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh R.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Luckenbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi K.","family":"Maranchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Shuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Staehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka N.","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki M.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.07.035_bib0001","first-page":"253","article-title":"Non-clear cell renal cell carcinoma: unpacking a messy term","volume":"23","author":"Bania","year":"2025","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0002","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.hoc.2023.04.019","article-title":"Renal cell carcinoma of variant histology: biology and therapies","volume":"37","author":"Msaouel","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438642","article-title":"Renal cell carcinoma of variant histology: new biologic understanding leads to therapeutic advances","volume":"44","author":"Salgia","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cncr.30314","article-title":"Renal cancer subtypes: should we be lumping or splitting for therapeutic decision making?","volume":"123","author":"Haake","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0006","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.urolonc.2025.07.020","article-title":"Developing biomarkers and methods of risk stratification: consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank","volume":"43","author":"Shapiro","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0007","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1287\/mnsc.9.3.458","article-title":"An experimental application of the Delphi method to the use of experts","volume":"9","author":"Dalkey","year":"1963","journal-title":"Manag Sci"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194674","article-title":"Interpreting randomized controlled trials","volume":"15","author":"Msaouel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0009","doi-asserted-by":"crossref","DOI":"10.1162\/99608f92.49e3c961","article-title":"Decoding randomized controlled trials: an information science perspective","volume":"6","author":"Msaouel","year":"2024","journal-title":"Harvard Data Sci Rev"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urolonc.2024.10.022","article-title":"Impact of postprogression therapies on overall survival: recommendations from the 2023 kidney cancer association think tank meeting","volume":"43","author":"Berg","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0011","series-title":"Demonstrating substantial evidence of effectiveness with one adequate and well-controlled clinical investigation and confirmatory evidence: guidance for industry (Draft guidance)","year":"2023"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0012","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/07357907.2022.2084621","article-title":"The big data paradox in clinical practice","volume":"40","author":"Msaouel","year":"2022","journal-title":"Cancer Invest"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0013","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jvir.2023.09.035","article-title":"Locoregional therapies in immunologically \u201ccold\u201d tumors: opportunities and clinical trial design considerations","volume":"35","author":"Msaouel","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-statistics-010814-020310","article-title":"There is individualized treatment. Why not individualized inference?","volume":"3","author":"Liu","year":"2016","journal-title":"Annu Rev Stat Appl"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0015","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","article-title":"Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer","volume":"392","author":"Srinivasan","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0016","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2025.05.019","article-title":"First-line Pembrolizumab plus Lenvatinib for advanced non-clear-cell renal cell carcinoma: updated results from the phase 2 KEYNOTE-B61 trial","volume":"88","author":"Voss","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0017","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65462-z","article-title":"Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence","volume":"16","author":"Soeung","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0019","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1214\/18-AOAS1161SF","article-title":"Statistical paradises and paradoxes in big data (I): law of large populations, big data paradox, and the 2016 US presidential election","volume":"12","author":"Meng","year":"2018","journal-title":"Ann Appl Stat"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0020","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of Cabozantinib and Nivolumab alone or with Ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153806","article-title":"A phase II clinical trial of Pembrolizumab efficacy and safety in advanced renal medullary carcinoma","volume":"15","author":"Nze","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdw413","article-title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","volume":"28","author":"Renfro","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0023","series-title":"Guidance for industry","article-title":"Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics","year":"2022"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0024","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0025","first-page":"125","article-title":"An overview of precision oncology basket and umbrella trials for clinicians","volume":"70","author":"Park","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0026","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s43441-021-00315-7","article-title":"Practical considerations and recommendations for Master Protocol Framework: basket, umbrella and platform trials","volume":"55","author":"Lu","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0027","series-title":"Guidance for industry","article-title":"Use of Bayesian methodology in clinical trials of drug and biological products","year":"2026"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0028","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/sim.1399","article-title":"Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes","volume":"22","author":"Thall","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0029","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1177\/1740774513497539","article-title":"Bayesian hierarchical modeling of patient subpopulations: efficient designs of phase II oncology clinical trials","volume":"10","author":"Berry","year":"2013","journal-title":"Clin Trials"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0031","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of Savolitinib vs Sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010958","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma","volume":"13","author":"Moussa","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0033","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1634\/theoncologist.2019-0372","article-title":"Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis","volume":"25","author":"Chahoud","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0034","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO-25-00234","article-title":"Tumor-intrinsic and microenvironmental determinants of impaired antitumor immunity in chromophobe renal cell carcinoma","volume":"43","author":"Labaki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0035","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","article-title":"Chromophobe renal cell carcinoma","volume":"41","author":"Henske","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0036","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejca.2018.08.014","article-title":"Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis","volume":"104","author":"Campbell","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0037","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","volume":"20","author":"Martinez Chanza","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0038","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.clgc.2019.11.012","article-title":"Clinical activity of Ipilimumab Plus Nivolumab in patients with metastatic non-clear cell renal cell carcinoma","volume":"18","author":"Gupta","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0039","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102359","article-title":"Targeting KIT with antibody-drug conjugates in chromophobe renal cell carcinoma","volume":"23","author":"Alchoueiry","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0041","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1038\/s41388-025-03562-2","article-title":"Targeting FSP1 to induce ferroptosis in chromophobe renal cell carcinoma","volume":"44","author":"Salem","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0042","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41590-022-01213-2","article-title":"Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies","volume":"23","author":"Kansler","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0043","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2025.43.16_suppl.4521","article-title":"AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE\/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study","volume":"43","author":"Cost","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0044","doi-asserted-by":"crossref","DOI":"10.1093\/biomtc\/ujaf043","article-title":"Precision generalized phase I-II designs","volume":"81","author":"Zhao","year":"2025","journal-title":"Biometrics"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0045","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-23-2222","article-title":"Novel clinical trial designs with dose optimization to improve long-term outcomes","volume":"29","author":"Thall","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0046","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/biom.12994","article-title":"A hybrid phase I-II\/III clinical trial design allowing dose re-optimization in phase III","volume":"75","author":"Chapple","year":"2019","journal-title":"Biometrics"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0047","article-title":"Framework for the use of external controls to evaluate treatment outcomes in precision oncology trials","volume":"8","author":"Siu","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0048","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.annonc.2021.12.015","article-title":"External control arms in oncology: current use and future directions","volume":"33","author":"Mishra-Kalyani","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0049","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1177\/0962280219880213","article-title":"Clustered allocation as a way of understanding historical controls: components of variation and regulatory considerations","volume":"29","author":"Collignon","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2026.07.035_bib0050","first-page":"S38","article-title":"Natural history and real-world data in rare diseases: applications, limitations, and future perspectives","volume":"62","author":"Liu","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100769","article-title":"Using real world data to support regulatory approval of drugs in rare diseases: a review of opportunities, limitations & a case example","volume":"45","author":"Gross","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104324","article-title":"The feasibility of using real world data as external control arms in oncology trials","volume":"30","author":"Lin","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0053","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0054","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/cncr.31578","article-title":"The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing","volume":"124","author":"Cajaiba","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0055","series-title":"Considerations for the inclusion of adolescent patients in adult oncology clinical trials: guidance for industry","year":"2019"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0056","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make Clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0057","series-title":"Guidance for industry (Draft guidance)","article-title":"Considerations for the design and conduct of externally controlled trials for drug and biological products","year":"2023"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0058","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/ijc.35129","article-title":"Improving the clinical meaning of surrogate endpoints: an empirical assessment of clinical progression in phase III oncology trials","volume":"155","author":"Sherry","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0059","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/jnci\/djaf378","article-title":"Differential censoring in overall survival in phase 3 oncology clinical trials","volume":"118","author":"Hsu","year":"2026","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0060","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djae028","article-title":"Association of differential censoring with survival and suboptimal control arms among oncology clinical trials","volume":"116","author":"Hsu","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71097","article-title":"Patient, physician, and assessor blinding in phase III randomized trials in oncology: a meta-epidemiological analysis","volume":"14","author":"Brown","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0062","article-title":"Increasing power in phase III oncology trials with multivariable regression: an empirical assessment of 535 primary end point analyses","volume":"8","author":"Sherry","year":"2024","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0063","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0064","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/19466315.2024.2375232","article-title":"Comment on \u201cusing randomization tests to address disruptions in clinical trials: a report from the NISS Ingram Olkin Forum Series on unplanned clinical trial disruptions\u201d","volume":"16","author":"Senn","year":"2024","journal-title":"Stat Biopharma Res"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0065","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0066","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12874-022-01799-z","article-title":"External control arm analysis: an evaluation of propensity score approaches, G-computation, and doubly debiased machine learning","volume":"22","author":"Loiseau","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0067","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-publhealth-032315-021644","article-title":"Bias analysis for uncontrolled confounding in the health sciences","volume":"38","author":"Arah","year":"2017","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0068","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/biom.12242","article-title":"Robust meta-analytic-predictive priors in clinical trials with historical control information","volume":"70","author":"Schmidli","year":"2014","journal-title":"Biometrics"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0069","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1541-0420.2011.01564.x","article-title":"Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials","volume":"67","author":"Hobbs","year":"2011","journal-title":"Biometrics"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pst.1589","article-title":"Use of historical control data for assessing treatment effects in clinical trials","volume":"13","author":"Viele","year":"2014","journal-title":"Pharm Stat"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0071","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clgc.2020.11.005","article-title":"Systemic therapies for the management of non-clear cell renal cell carcinoma: what works, what doesn't, and what the future holds","volume":"19","author":"Zoumpourlis","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0072","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euo.2024.09.002","article-title":"Neoadjuvant and Adjuvant immune-based approach for renal cell carcinoma: pros, cons, and future directions","volume":"8","author":"Marandino","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0073","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163923","article-title":"A causal framework for making individualized treatment decisions in oncology","volume":"14","author":"Msaouel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0074","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.eururo.2025.01.014","article-title":"Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma","volume":"87","author":"Bedke","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0075","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant Pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.04.002","article-title":"Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma","volume":"37","author":"Msaouel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0077","article-title":"Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling","volume":"6","author":"Msaouel","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0079","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of Pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0080","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in combination with Atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study","volume":"39","author":"Pal","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0081","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13023-022-02388-5","article-title":"What role can decentralized trial designs play to improve rare disease studies?","volume":"17","author":"Moore","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0082","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming barriers to clinical trial enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0083","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-023-02693-7","article-title":"Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective","volume":"18","author":"Ghadessi","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0084","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-100051","article-title":"Designing clinical trials for patients with rare cancers: connecting the zebras","volume":"45","author":"Subbiah","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/OP.24.00261","article-title":"State of geographic access to cancer treatment trials in the United States: are studies located where patients live?","volume":"21","author":"Kirkwood","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0086","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.urolonc.2023.01.022","article-title":"Factors associated with clinical trial participation for patients with renal cell carcinoma","volume":"41","author":"Shinder","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0087","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.22998","article-title":"Evaluation of technology-enabled monitoring of patient-reported outcomes to detect and treat toxic effects linked to immune checkpoint inhibitors","volume":"4","author":"Msaouel","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0088","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.22.00358","article-title":"Decentralized clinical trials in oncology: are we ready for a virtual-first paradigm?","volume":"41","author":"Fu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0089","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/PPO.0000000000000695","article-title":"Telemedicine and cancer clinical research: opportunities for transformation","volume":"30","author":"von Itzstein","year":"2024","journal-title":"Cancer J"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0090","doi-asserted-by":"crossref","DOI":"10.2196\/31255","article-title":"The use of telemedicine in cancer clinical trials: connect-patient-to-doctor prospective study","volume":"8","author":"Meghiref","year":"2022","journal-title":"JMIR Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0091","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/cts.13411","article-title":"Leveraging patient-centric sampling for clinical drug development and decentralized clinical trials: promise to reality","volume":"15","author":"Maass","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0092","article-title":"Application of real-world data to external control groups in oncology clinical trial drug development","volume":"11","author":"Yap","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0093","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s43441-024-00627-4","article-title":"The next horizon of drug development: external control arms and innovative tools to enrich clinical trial data","volume":"58","author":"Zou","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0094","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70117","article-title":"Decentralized clinical trials in the era of real-world evidence: a statistical perspective","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0095","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf053","article-title":"Sample-size determination for decentralized clinical trials","volume":"54","author":"Tian","year":"2025","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0096","article-title":"Comprehensive genomic analysis of metastatic non-clear-cell renal cell carcinoma to identify therapeutic targets","volume":"3","author":"Carlo","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0097","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1093\/oncolo\/oyad040","article-title":"Comprehensive genomic profiling of NF2-mutated kidney tumors reveals potential targets for therapy","volume":"28","author":"Hacking","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0098","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-25-2871","article-title":"Integrative clinical and molecular evaluation of renal cell carcinoma with Merlin protein deficiency and biallelic loss of NF2","volume":"32","author":"Yekeduz","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0099","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1038\/s41591-025-04029-3","article-title":"YAP\/TEAD inhibitor VT3989 in solid tumors: a phase 1\/2 trial","volume":"31","author":"Yap","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","article-title":"A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors","volume":"40","author":"Tolcher","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0101","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0102","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0103","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","article-title":"Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study","volume":"25","author":"Iliopoulos","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0104","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70239","article-title":"Targeting HIF-2alpha in renal cell carcinoma: expanding upon belzutifan","volume":"132","author":"Rodriguez","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0106","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0107","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cct.2017.09.006","article-title":"A 2-in-1 adaptive phase 2\/3 design for expedited oncology drug development","volume":"64","author":"Chen","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0109","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/sim.10129","article-title":"A seamless phase II\/III design with dose optimization for oncology drug development","volume":"43","author":"Li","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0110","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on- and off-ramps of oncology accelerated approval","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0111","series-title":"Guidance for industry (draft guidance)","article-title":"Clinical trial considerations to support accelerated approval of oncology therapeutics","year":"2023"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0112","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0113","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0114","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/carcin\/bgh017","article-title":"Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice","volume":"25","author":"Kleymenova","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2408549121","article-title":"Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: initial experience and lessons learned","volume":"121","author":"Stransky","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0116","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s43018-023-00584-1","article-title":"Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer","volume":"4","author":"Perelli","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0117","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2209639120","article-title":"SMARCB1 regulates the hypoxic stress response in sickle cell trait","volume":"120","author":"Soeung","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0118","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/nprot.2014.108","article-title":"Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing","volume":"9","author":"Pavia-Jimenez","year":"2014","journal-title":"Nat Protoc"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0119","doi-asserted-by":"crossref","first-page":"FSO737","DOI":"10.2144\/fsoa-2021-0019","article-title":"Drug discovery oncology in a mouse: concepts, models and limitations","volume":"7","author":"Long","year":"2021","journal-title":"Future Sci OA"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: a maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0121","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","article-title":"Mouse models for cancer immunotherapy research","volume":"8","author":"Olson","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0122","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121454","article-title":"Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy","volume":"283","author":"Virumbrales-Munoz","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110760","article-title":"Efficient proximal tubule-on-chip model from hiPSC-derived kidney organoids for functional analysis of renal transporters","volume":"27","author":"Ma","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0125","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0126","article-title":"Kidney organoid and microphysiological Kidney chip models to accelerate drug development and reduce animal testing","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0127","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41420-025-02407-x","article-title":"Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41746-024-01188-4","article-title":"From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling","volume":"7","author":"Wang","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","article-title":"Organs-on-chips: into the next decade","volume":"20","author":"Low","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/sim.10307","article-title":"To explain, to predict, or to describe: figuring out the study goal [Commentary on \"On the Uses and Abuses of Regression Models\" by Carlin and Moreno-Betancur]","volume":"44","author":"Shmueli","year":"2025","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0131","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.socscimed.2017.12.005","article-title":"Understanding and misunderstanding randomized controlled trials","volume":"210","author":"Deaton","year":"2018","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0132","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/sim.8426","article-title":"Extending inferences from a randomized trial to a new target population","volume":"39","author":"Dahabreh","year":"2020","journal-title":"Stat Med"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0133","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.46302","article-title":"Transportability analysis-a tool for extending trial results to a representative target population","volume":"7","author":"Inoue","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0134","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/00037028251330324","article-title":"Perspective on the capacity of the Rashomon Effect in multivariate data analysis","volume":"79","author":"Kalivas","year":"2025","journal-title":"Appl Spectrosc"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0135","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201800041","article-title":"Same redox evidence but different physiological \u201cstories\u201d: the Rashomon effect in biology","volume":"40","author":"Nikolaidis","year":"2018","journal-title":"Bioessays"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0136","doi-asserted-by":"crossref","DOI":"10.1162\/99608f92.106bb670","article-title":"User-guided interpretable models: Rashomon effect, interaction, and computation","volume":"7","author":"Liu","year":"2025","journal-title":"Harvard Data Sci Rev"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0137","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrurol.2010.234","article-title":"Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC","volume":"8","author":"Yamasaki","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2026.07.035_bib0138","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMsb2512695","article-title":"FDA's new plausible mechanism pathway","volume":"393","author":"Prasad","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926007039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:35:52Z","timestamp":1791747352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926007039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":138,"alternative-id":["S1078143926007039"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.035","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}